SCHEMBL3606205

SCHEMBL3606205

COc1ccc2c(c1)ncn2CC(=O)NCCN(C)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.45
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
CDYL2 Q8N8U2 1/20 0.40
CDYL Q9Y232 1/20 0.40
CDY1; CDY1B Q9Y6F8 1/20 0.40
HPGDS O60760 1/20 0.39
BRD4 O60885 1/20 0.39
KMT2A Q03164 3/20 0.39
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
ATM Q13315 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367265 0.93 MTNR1A (0.52) TP53MAPTALDH1A1MTNR1AMTNR1B
SCHEMBL3602186 0.88 TP53 (0.41) TP53MAPTALDH1A1KMT2AHPGD
SCHEMBL3597098 0.87 KMT2A (0.42) TP53MAPTALDH1A1L3MBTL1KMT2A
SCHEMBL3599700 0.84 ATM (0.42) TP53MAPTALDH1A1KMT2AHPGD
SCHEMBL3606208 0.83 TP53 (0.44) TP53MAPTALDH1A1MTNR1AMTNR1B
SCHEMBL3605821 0.83 CCNE1 (0.43) TP53MAPTL3MBTL1KMT2AHPGD
SCHEMBL5345349 0.82 TRPA1 (0.43) TP53MAPTALDH1A1L3MBTL1KMT2A
SCHEMBL13115367 0.81 TRPA1 (0.42) TP53MAPTALDH1A1L3MBTL1KMT2A
SCHEMBL13115590 0.79 ATM (0.47) ATM
SCHEMBL3608391 0.77 GAA (0.42) TP53MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 TP53 1777/4885MAPT 2809/4885ALDH1A1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.